The US Food and Drug Administration (FDA) recently approved the use of immune checkpoint inhibitors (ICIs), such as anti-PD-1 or PD-L1 monoclonal antibodies (mAb), as third-line treatments against advanced cancers of different types, including gastric cancer3,4. Here, CD274 is linked to cancer.